NYSE:ALR Alere (ALR) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free ALR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.32▼$1.3250-Day Range N/A52-Week Range$34.41▼$51.00VolumeN/AAverage Volume40,839 shsMarket Capitalization$43.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Alere alerts: Email Address Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Alere Stock (NYSE:ALR)Alere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.Read More Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 ALR Stock News HeadlinesApril 11, 2024 | businesswire.comAlerisLife and Five Star Senior Living Awarded Great Place to Work® CertificationDecember 28, 2023 | morningstar.comAlro SA ALRApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 18, 2023 | thestreet.comAlere (ALR) Stock Plummets, Rejects Abbott's Request to End MergerApril 9, 2023 | yahoo.comTrek's latest aluminium Émonda ALR is lighter and racier than beforeFebruary 3, 2023 | finance.yahoo.comABP Acquisition to Acquire AlerisLife for $1.31 Per ShareNovember 2, 2022 | finance.yahoo.comAlerisLife Inc. Announces Third Quarter 2022 ResultsOctober 17, 2022 | finance.yahoo.comAlerisLife Announces the Appointment of Philip Benjamson as a Senior Vice President and Chief Operating OfficerApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.October 16, 2022 | seekingalpha.comAbbott Q3 Earnings Preview: I'm Still Not A Buyer (NYSE:ABT) - Seeking AlphaOctober 11, 2022 | prnewswire.comCritical Care Diagnostics Market to Exceed US$ 1.7 Billion by 2031 Amid Rising Prevalence of Chronic Diseases - PR NewswireOctober 11, 2022 | prnewswire.comDrug Screening Market is expected to generate a revenue of USD 22.16 Billion by 2030, Globally, at 10.6% CAGR: Verified Market Research® - PR NewswireOctober 7, 2022 | benzinga.comAt 5.4% CAGR, Arbovirus Testing Market Size is Expected to Reach US$ 1919.7 Mn by 2030 | Market Expected - BenzingaOctober 5, 2022 | benzinga.comOutlook on the Isothermal Nucleic Acid Amplification Technology Global Market to 2030 - Featuring Alere, - BenzingaOctober 5, 2022 | finance.yahoo.comAlerisLife Inc. Third Quarter 2022 Conference Call Scheduled for Thursday, November 3rdOctober 5, 2022 | finance.yahoo.comGlobal Infectious Disease In Vitro Diagnostics Market Report (2022 to 2030) - High Demand for PoC Facilities is Driving Growth - Yahoo FinanceOctober 5, 2022 | globenewswire.comOutlook on the Isothermal Nucleic Acid Amplification Technology Global Market to 2030 - Featuring Alere, Biomerieux and Lucigen Among Others - GlobeNewswireSeptember 19, 2022 | finance.yahoo.comAlerisLife Announces the Appointment of Heather Pereira as Senior Vice President, Chief Financial Officer and TreasurerSeptember 9, 2022 | finance.yahoo.comAlerisLife Inc. (ALR)August 13, 2022 | investing.comALR_pb Historical DataAugust 6, 2022 | finance.yahoo.comAlerisLife (NASDAQ:ALR) adds US$18m to market cap in the past 7 days, though investors from five years ago are still down 89%August 3, 2022 | nasdaq.comAlere Inc. Q2 Loss decreases, but misses estimatesAugust 3, 2022 | finance.yahoo.comAlerisLife Inc. Announces Second Quarter 2022 ResultsJuly 22, 2022 | reuters.comColumn: Aluminium producers feel the margin pain as price slumpsJuly 6, 2022 | finance.yahoo.comAlerisLife Inc. Second Quarter 2022 Conference Call Scheduled for Thursday, August 4thJune 28, 2022 | finance.yahoo.comAlerisLife Provides a Business UpdateJune 14, 2022 | streetinsider.comMainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission - StreetInsider.comSee More Headlines Receive ALR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alere and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2016Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Skilled nursing care facilities Sub-IndustryHealth Care Supplies Current SymbolNYSE:ALR CUSIP01449J10 CIK1145460 Webwww.alere.com Phone+1-781-6473900Fax617-796-8385Employees10,400Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,920,000.00 Net Margins-5.34% Pretax Margin-5.29% Return on Equity-20.78% Return on Assets-9.02% Debt Debt-to-Equity Ratio0.45 Current Ratio1.58 Quick Ratio1.58 Sales & Book Value Annual Sales$934.59 million Price / Sales0.05 Cash FlowN/A Price / Cash FlowN/A Book Value$5.72 per share Price / Book0.23Miscellaneous Outstanding Shares32,610,000Free Float29,870,000Market Cap$43.05 million OptionableOptionable Beta0.85 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesGregg J. PowersIndependent Chairman of the BoardNamal NawanaPresident, Chief Executive Officer, DirectorJames F. HinrichsChief Financial Officer, Executive Vice PresidentDaniella CrampGlobal President - Cardiometabolic Business UnitSanjay MalkaniGlobal President - ToxicologyAvi PelossofGlobal President - Infectious Disease Business UnitEllen Chiniara J.D.Senior Vice President, General Counsel, Chief Ethics and Compliance Officer, SecretaryRobert HargadonSenior Vice President - Global Human ResourcesJohn Bridgen Ph.D.Senior Vice President - Business DevelopmentMark GladwellSenior Vice President - Global OperationsMore ExecutivesKey CompetitorsCleneNASDAQ:CLNNApollomicsNASDAQ:APLMDarioHealthNASDAQ:DRIONextCureNASDAQ:NXTCBionano GenomicsNASDAQ:BNGOView All Competitors ALR Stock Analysis - Frequently Asked Questions How were Alere's earnings last quarter? Alere Inc. (NYSE:ALR) issued its quarterly earnings results on Friday, November, 4th. The medical research company reported $0.19 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.54 by $0.35. The medical research company earned $582 million during the quarter, compared to the consensus estimate of $605.50 million. Alere had a negative trailing twelve-month return on equity of 20.78% and a negative net margin of 5.34%. The firm's quarterly revenue was down 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.10) earnings per share. What other stocks do shareholders of Alere own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alere investors own include Morgan Stanley (MS), BioTelemetry (BEAT), Abbott Laboratories (ABT), FireEye (FEYE), Twitter (TWTR), Allergan (AGN), AEGR (AEGR), Ashmore Group (ASHM), Chembio Diagnostics (CEMI) and Capitala Finance (CPTA). This page (NYSE:ALR) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alere Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
